AU6309698A
(en)
*
|
1997-03-12 |
1998-09-29 |
Banyu Pharmaceutical Co., Ltd. |
Drugs containing aminopyridine derivatives as the active ingredient
|
GB9709815D0
(en)
*
|
1997-05-14 |
1997-07-09 |
Merck Sharp & Dohme |
Therapeutic method
|
AU744297B2
(en)
|
1997-07-03 |
2002-02-21 |
Neurogen Corporation |
Certain diarylimidazole derivatives; a new class of NPY specific ligands
|
AU8914798A
(en)
*
|
1997-08-25 |
1999-03-16 |
Bayer Corporation |
Heterocyclic ketones as npy y5 antagonists
|
WO1999027965A1
(en)
*
|
1997-11-28 |
1999-06-10 |
Banyu Pharmaceutical Co., Ltd. |
Antihyperlipemic agents
|
US6187777B1
(en)
|
1998-02-06 |
2001-02-13 |
Amgen Inc. |
Compounds and methods which modulate feeding behavior and related diseases
|
PT1076644E
(en)
*
|
1998-04-29 |
2004-10-29 |
Ortho Mcneil Pharm Inc |
AMINOTETHALINES REPLACED IN EITHER AS LIGANDS FOR THE NEUROPEPTIDEOY Y5 RECEPTOR USEFUL IN THE TREATMENT OF OBESITY AND OTHER PERTURBACES
|
AU756797B2
(en)
|
1998-11-10 |
2003-01-23 |
Banyu Pharmaceutical Co., Ltd. |
Spiro-indolines as Y5 receptor antagonists
|
US6407120B1
(en)
|
1999-02-18 |
2002-06-18 |
Pfizer Inc. |
Neuropeptide Y antagonists
|
AU3840000A
(en)
|
1999-04-20 |
2000-11-02 |
Meiji Seika Kaisha Ltd. |
Tricyclic compounds
|
US6989379B1
(en)
|
1999-04-22 |
2006-01-24 |
H. Lundbick A/S |
Selective NPY (Y5) antagonists
|
PT1183245E
(en)
|
1999-04-22 |
2007-07-12 |
Lundbeck & Co As H |
Selective npy (y5) antagonists
|
US6218408B1
(en)
|
1999-06-30 |
2001-04-17 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (bicyclics)
|
US6340683B1
(en)
|
1999-04-22 |
2002-01-22 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (triazines)
|
US6841552B1
(en)
|
1999-05-05 |
2005-01-11 |
Ortho-Mcneil Pharmaceutical, Inc. |
3a,4,5,9b-tetrahydro-1H-benz[e]indol-2-yl amine-derived neuropeptide Y receptors ligands useful in the treatment of obesity and other disorders
|
EP1177172A1
(en)
*
|
1999-05-05 |
2002-02-06 |
Ortho-McNeil Pharmaceutical, Inc. |
3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
|
US6214853B1
(en)
|
1999-06-30 |
2001-04-10 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (bicyclics)
|
US6222040B1
(en)
|
1999-06-30 |
2001-04-24 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (tricyclics)
|
US7273880B2
(en)
|
1999-06-30 |
2007-09-25 |
H. Lunbeck A/S |
Selective NPY (Y5) antagonists
|
US6225330B1
(en)
|
1999-06-30 |
2001-05-01 |
Synaptic Pharmaceutical Corporation |
Selective NPY (Y5) antagonists (tricyclics)
|
EP1220836A2
(en)
|
1999-10-15 |
2002-07-10 |
Bristol-Myers Squibb Pharma Company |
Benzylcycloalkyl amines as modulators of chemokine receptor activity
|
US6291499B1
(en)
*
|
1999-10-29 |
2001-09-18 |
Merck & Co., Inc. |
2-cyclohexyl benzimidazole NMDA/NR2B antagonists
|
MXPA02004985A
(en)
|
1999-11-26 |
2003-10-14 |
Shionogi & Co |
Npyy5 antagonists.
|
JP4988128B2
(en)
|
2000-07-13 |
2012-08-01 |
イーライ リリー アンド カンパニー |
β3 adrenergic agonist
|
CA2460594A1
(en)
|
2001-10-01 |
2003-04-10 |
Taisho Pharmaceutical Co., Ltd. |
Mch receptor antagonists
|
CA2403307A1
(en)
*
|
2001-10-23 |
2003-04-23 |
Neurogen Corporation |
Substituted 2-cyclohexyl-4-phenyl-1h-imidazole derivatives
|
ES2193875B2
(en)
|
2002-04-09 |
2005-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
DERIVATIVES OF BENZOXAZINONA, ITS PREPARATION AND ITS APPLICATION AS MEDICATIONS.
|
US7105526B2
(en)
|
2002-06-28 |
2006-09-12 |
Banyu Pharmaceuticals Co., Ltd. |
Benzimidazole derivatives
|
EP1398032A1
(en)
*
|
2002-09-10 |
2004-03-17 |
PheneX Pharmaceuticals AG |
4-Oxo-quinazolines as LXR nuclear receptor binding compounds
|
EP1407774A1
(en)
*
|
2002-09-10 |
2004-04-14 |
LION Bioscience AG |
2-Amino-4-quinazolinones as LXR nuclear receptor binding compounds
|
DE60323133D1
(en)
*
|
2002-12-13 |
2008-10-02 |
Smithkline Beecham Corp |
CYCLOHEXYL COMPOUNDS AS CCR5 ANTAGONISTS
|
US20040192583A1
(en)
*
|
2002-12-19 |
2004-09-30 |
Satyanarayana Medicherla |
Treatment of obesity and associated conditions with TGF-beta inhibitors
|
US7772188B2
(en)
|
2003-01-28 |
2010-08-10 |
Ironwood Pharmaceuticals, Inc. |
Methods and compositions for the treatment of gastrointestinal disorders
|
JP2004315511A
(en)
*
|
2003-03-31 |
2004-11-11 |
Taisho Pharmaceut Co Ltd |
Mch receptor antagonist
|
EP1611109A4
(en)
*
|
2003-03-31 |
2009-06-24 |
Taisho Pharmaceutical Co Ltd |
Novel quinazoline derivatives and methods of treatment related to the use thereof
|
DE602004026289D1
(en)
|
2003-05-05 |
2010-05-12 |
Probiodrug Ag |
Glutaminyl INHIBITORS
|
DE602004022819D1
(en)
|
2003-06-06 |
2009-10-08 |
Vertex Pharma |
TRANSPORTER OF ATP-BINDING CASSETTE
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
ES2222833B1
(en)
|
2003-07-30 |
2006-03-01 |
Laboratorios Del Dr. Esteve, S.A. |
1,4-DISPOSED PIPERIDINIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICINES.
|
WO2005028438A1
(en)
|
2003-09-22 |
2005-03-31 |
Banyu Pharmaceutical Co., Ltd. |
Novel piperidine derivative
|
JP2007510629A
(en)
|
2003-10-22 |
2007-04-26 |
イーライ リリー アンド カンパニー |
Novel MCH receptor antagonist
|
ZA200603165B
(en)
|
2003-11-03 |
2007-07-25 |
Probiodrug Ag |
Combinations useful for the treatment of neuronal disorders
|
GB0400193D0
(en)
*
|
2004-01-07 |
2004-02-11 |
Astrazeneca Ab |
Therapeutic agents
|
AU2005210004B2
(en)
|
2004-02-05 |
2010-10-28 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
WO2005095357A2
(en)
*
|
2004-03-30 |
2005-10-13 |
Taisho Pharmaceutical Co., Ltd. |
Pyrimidine derivatives and methods of treatment related to the use thereof
|
EP2305352A1
(en)
|
2004-04-02 |
2011-04-06 |
Merck Sharp & Dohme Corp. |
5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
|
WO2006014482A1
(en)
*
|
2004-07-08 |
2006-02-09 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Pyrimidine derivatives useful as inhibitors of pkc-theta
|
EP1814590B2
(en)
|
2004-11-01 |
2013-12-11 |
Amylin Pharmaceuticals, Inc. |
Treatment of obesity and related disorders
|
US8394765B2
(en)
|
2004-11-01 |
2013-03-12 |
Amylin Pharmaceuticals Llc |
Methods of treating obesity with two different anti-obesity agents
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
US20090286723A1
(en)
|
2005-02-11 |
2009-11-19 |
Amylin Pharmaceuticals, Inc. |
Hybrid Polypeptides with Selectable Properties
|
US7737155B2
(en)
|
2005-05-17 |
2010-06-15 |
Schering Corporation |
Nitrogen-containing heterocyclic compounds and methods of use thereof
|
ES2574014T3
(en)
|
2005-05-30 |
2016-06-14 |
Msd K.K. |
Novel Piperidine Derivative
|
JP5118029B2
(en)
|
2005-06-14 |
2013-01-16 |
タイゲン バイオテクノロジー カンパニー,リミテッド |
Pyrimidine compounds
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
EP1916239A4
(en)
|
2005-08-10 |
2009-10-21 |
Banyu Pharma Co Ltd |
Pyridone compound
|
BRPI0614649A2
(en)
|
2005-08-11 |
2011-04-12 |
Amylin Pharmaceuticals Inc |
hybrid polypeptides with selectable properties
|
EP1921065B1
(en)
|
2005-08-24 |
2010-10-20 |
Banyu Pharmaceutical Co., Ltd. |
Phenylpyridone derivative
|
WO2007029847A1
(en)
|
2005-09-07 |
2007-03-15 |
Banyu Pharmaceutical Co., Ltd. |
Bicyclic aromatic substituted pyridone derivative
|
EP1940842B1
(en)
|
2005-09-29 |
2012-05-30 |
Merck Sharp & Dohme Corp. |
Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
|
BRPI0617621A2
(en)
|
2005-10-21 |
2011-08-02 |
Novartis Ag |
combination of organic compounds
|
AU2006307046A1
(en)
|
2005-10-27 |
2007-05-03 |
Msd K.K. |
Novel benzoxathiin derivative
|
MY146564A
(en)
|
2005-11-10 |
2012-08-30 |
Msd Kk |
Aza-substituted spiro derivatives
|
BRPI0710950A2
(en)
|
2006-04-28 |
2012-06-26 |
Shionogi & Co |
amine derivative having npi 53 y5 receptor antagonistic activity a61p 3/04 a61p 9/04 a61p 9/12 a61p 15/00 a61p 25/08 a61p 25/20 a61p 25/24 a61p 43/00 c07c 311/07 c07c 317 / 36 c07d 207/325 c07d 211/14 c07d 213/38 c07d 213/74 c07d 213/82 c07d 215/38 c07d 217/04 c07d 217/14 c07d 217/22 c07d 219/10 c07d 231/38 c07d 233/61 c07d 235/30 c07d 237/20 c07d 237/22 c07d 237/34 c07d 239/42 c07d 241/20 c07d 261/14 c07d 261/20 c07d 263/58 c07d 265/30 c07d 265/36 c07d 267/14 c07d 275 / 02 c07d 277/28 c07d 277/62 c07d 277/82 c07d 295/12 c07d 295/18 c07d 333/36 c07d 333/40 c07d 333/66 c07d 333/72 c07d 403/04 c07d 409/04 c07d 413/04 c07d 417/12 c07d 498/04 c07d 513/04
|
EP2698157B1
(en)
|
2006-09-22 |
2015-05-20 |
Merck Sharp & Dohme Corp. |
Method of treatment using fatty acid synthesis inhibitors
|
WO2008038692A1
(en)
|
2006-09-28 |
2008-04-03 |
Banyu Pharmaceutical Co., Ltd. |
Diaryl ketimine derivative
|
WO2008055945A1
(en)
|
2006-11-09 |
2008-05-15 |
Probiodrug Ag |
3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
|
WO2008065141A1
(en)
|
2006-11-30 |
2008-06-05 |
Probiodrug Ag |
Novel inhibitors of glutaminyl cyclase
|
ZA200905537B
(en)
|
2007-03-01 |
2010-10-27 |
Probiodrug Ag |
New use of glutaminyl cyclase inhibitors
|
AU2008233662B2
(en)
|
2007-04-02 |
2012-08-23 |
Msd K.K. |
Indoledione derivative
|
JP5667440B2
(en)
|
2007-04-18 |
2015-02-12 |
プロビオドルグ エージー |
Thiourea derivatives as glutaminyl cyclase inhibitors
|
US7879802B2
(en)
|
2007-06-04 |
2011-02-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
SA08290668B1
(en)
|
2007-10-25 |
2012-02-12 |
شيونوجي آند كو.، ليمتد |
Amine Derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
|
PE20091309A1
(en)
*
|
2007-12-21 |
2009-09-30 |
Astrazeneca Ab |
CYCLOHEXYL DERIVATIVES AS ACETYL COENZYME CARBOXYLASE INHIBITORS
|
CA2714617A1
(en)
|
2008-03-06 |
2009-09-11 |
Banyu Pharmaceutical Co., Ltd. |
Alkylaminopyridine derivative
|
US20110015198A1
(en)
|
2008-03-28 |
2011-01-20 |
Banyu Pharmaceutical Co., Inc. |
Diarylmethylamide derivative having melanin-concentrating hormone receptor antagonism
|
PT2268635E
(en)
|
2008-04-21 |
2015-10-06 |
Taigen Biotechnology Co Ltd |
Heterocyclic compounds
|
EP3239170B1
(en)
|
2008-06-04 |
2019-03-20 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
EP2301936A1
(en)
|
2008-06-19 |
2011-03-30 |
Banyu Pharmaceutical Co., Ltd. |
Spirodiamine-diarylketoxime derivative
|
EP3241839B1
(en)
|
2008-07-16 |
2019-09-04 |
Bausch Health Ireland Limited |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
|
EP2319841A1
(en)
|
2008-07-30 |
2011-05-11 |
Msd K.K. |
(5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative
|
CA2741125A1
(en)
|
2008-10-22 |
2010-04-29 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
CA2741644C
(en)
|
2008-10-30 |
2013-05-07 |
Merck Sharp & Dohme Corp. |
Isonicotinamide orexin receptor antagonists
|
WO2010051206A1
(en)
|
2008-10-31 |
2010-05-06 |
Merck Sharp & Dohme Corp. |
Novel cyclic benzimidazole derivatives useful anti-diabetic agents
|
WO2010056847A2
(en)
|
2008-11-13 |
2010-05-20 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
EP2379547A1
(en)
|
2008-12-16 |
2011-10-26 |
Schering Corporation |
Pyridopyrimidine derivatives and methods of use thereof
|
US20110243940A1
(en)
|
2008-12-16 |
2011-10-06 |
Schering Corporation |
Bicyclic pyranone derivatives and methods of use thereof
|
WO2010101247A1
(en)
|
2009-03-05 |
2010-09-10 |
塩野義製薬株式会社 |
Cyclohexane derivative having npy y5 receptor antagonism
|
US8227618B2
(en)
|
2009-04-23 |
2012-07-24 |
Shionogi & Co., Ltd. |
Amine-derivatives having NPY Y5 receptor antagonistic activity and the uses thereof
|
PL2473487T3
(en)
*
|
2009-09-03 |
2017-07-31 |
Bristol-Myers Squibb Company |
Quinazolines as potassium ion channel inhibitors
|
MX2012002993A
(en)
|
2009-09-11 |
2012-04-19 |
Probiodrug Ag |
Heterocylcic derivatives as inhibitors of glutaminyl cyclase.
|
US8895596B2
(en)
|
2010-02-25 |
2014-11-25 |
Merck Sharp & Dohme Corp |
Cyclic benzimidazole derivatives useful as anti-diabetic agents
|
JP6026284B2
(en)
|
2010-03-03 |
2016-11-16 |
プロビオドルグ エージー |
Inhibitors of glutaminyl cyclase
|
MX2012010470A
(en)
|
2010-03-10 |
2012-10-09 |
Probiodrug Ag |
Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5).
|
US8541596B2
(en)
|
2010-04-21 |
2013-09-24 |
Probiodrug Ag |
Inhibitors
|
AU2011245499B2
(en)
|
2010-04-30 |
2014-09-25 |
Merck Sharp & Dohme Corp. |
Novel beta 3 adrenergic receptor agonists
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
EP2677869B1
(en)
|
2011-02-25 |
2017-11-08 |
Merck Sharp & Dohme Corp. |
Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
|
WO2012123563A1
(en)
|
2011-03-16 |
2012-09-20 |
Probiodrug Ag |
Benz imidazole derivatives as inhibitors of glutaminyl cyclase
|
AR088352A1
(en)
|
2011-10-19 |
2014-05-28 |
Merck Sharp & Dohme |
ANTAGONISTS OF THE RECEIVER OF 2-PIRIDILOXI-4-NITRILE OREXINE
|
AU2013296470B2
(en)
|
2012-08-02 |
2016-03-17 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
AU2014219020A1
(en)
|
2013-02-22 |
2015-07-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2014139388A1
(en)
|
2013-03-14 |
2014-09-18 |
Merck Sharp & Dohme Corp. |
Novel indole derivatives useful as anti-diabetic agents
|
CA2905435A1
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
US9708367B2
(en)
|
2013-03-15 |
2017-07-18 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase and their uses
|
JP6606491B2
(en)
|
2013-06-05 |
2019-11-13 |
シナジー ファーマシューティカルズ インコーポレイテッド |
Ultra high purity agonist of guanylate cyclase C, method for producing and using the same
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
JP6769963B2
(en)
|
2014-08-29 |
2020-10-14 |
ティエエッセ ファルマ ソチエタ レスポンサビリタ リミタータ |
Inhibitor of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
|
AU2017342083A1
(en)
|
2016-10-14 |
2019-04-11 |
Tes Pharma S.R.L. |
Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
Antidiabetic heterocyclic compounds
|
EP3558298A4
(en)
|
2016-12-20 |
2020-08-05 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
EP3461819B1
(en)
|
2017-09-29 |
2020-05-27 |
Probiodrug AG |
Inhibitors of glutaminyl cyclase
|
KR20210111248A
(en)
|
2018-11-20 |
2021-09-10 |
테스 파마 에스.알.엘. |
Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase
|
WO2020113094A1
(en)
|
2018-11-30 |
2020-06-04 |
Nuvation Bio Inc. |
Pyrrole and pyrazole compounds and methods of use thereof
|
WO2020167706A1
(en)
|
2019-02-13 |
2020-08-20 |
Merck Sharp & Dohme Corp. |
5-alkyl pyrrolidine orexin receptor agonists
|
CN114340670A
(en)
|
2019-07-11 |
2022-04-12 |
普拉克西斯精密药物股份有限公司 |
Formulations of T-type calcium channel modulators and methods of use thereof
|
WO2021026047A1
(en)
|
2019-08-08 |
2021-02-11 |
Merck Sharp & Dohme Corp. |
Heteroaryl pyrrolidine and piperidine orexin receptor agonists
|
CR20230089A
(en)
|
2020-08-18 |
2023-04-11 |
Merck Sharp & Dohme Llc |
Bicycloheptane pyrrolidine orexin receptor agonists
|
CN114315802B
(en)
*
|
2021-12-14 |
2023-06-16 |
西安医学院 |
Quinazoline nitrogen-containing heterocyclic derivative, preparation method and application
|
WO2023121429A1
(en)
*
|
2021-12-24 |
2023-06-29 |
아주대학교산학협력단 |
Novel compound for improving sleep or use thereof
|